Edaravone

CHEMBL290916 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

174.2 g/mol

LogP

1.3

Phase

4

A free radical scavenger used to slow the progression of amyotrophic lateral sclerosis (ALS) and to treat patients following acute ischemic stroke. It protects nerve and brain cells from oxidative damage.

Peso molecular

174,2000 g/mol

LogP

1,30

TPSA

32,70 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Enfermedad cardiovascular Ictus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1=NN(c2ccccc2)C(=O)C1

InChI

InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3

Molecular Formula

C10H10N2O

HBD / HBA

- / 2

Enlaces Rotables

1

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A free radical scavenger used to slow the progression of amyotrophic lateral sclerosis (ALS) and to treat patients following acute ischemic stroke. It protects nerve and brain cells from oxidative damage.

Yes, Edaravone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL290916. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4021. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Edaravone en PillFYI

Estructura

Datos Rápidos

Fórmula: C10H10N2O
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.